Paper41783166
Histone deacetylases: Function in tumor development and therapeutic prospects (Review).
Lin R and 3 others. Oncol Lett, 2026. Cited by 4 papers, by iCite.
Cite this record
ConductScience Library. Histone deacetylases: Function in tumor development and therapeutic prospects (Review). Papers, record 41783166. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41783166
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References175
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 40380049 | Epigenetic reprogramming and antitumor immune responses in gliomas: a systematic review. | Med Oncol | 2025 | https://conductscience.org/library/papers/40380049 | PubMed |
| 2 | 36230631 | Histone Deacetylase Inhibitors as a Therapeutic Strategy to Eliminate Neoplastic "Stromal" Cells from Giant Cell Tumors of Bone. | Cancers (Basel) | 2022 | https://conductscience.org/library/papers/36230631 | PubMed |
| 3 | 32599665 | Histone deacetylase inhibition prevents the growth of primary and metastatic osteosarcoma. | Int J Cancer | 2020 | https://conductscience.org/library/papers/32599665 | PubMed |
| 4 | 41563767 | MIG-6 Regulates HDAC1-Mediated Angiogenesis and Tumorigenesis in PTEN-Deficient Endometrioid Endometrial Cancer. | Mol Cancer Res | 2026 | https://conductscience.org/library/papers/41563767 | PubMed |
| 5 | 39676171 | HDACi combination therapy with IDO1i remodels the tumor microenvironment and boosts antitumor efficacy in colorectal cancer with microsatellite stability. | J Nanobiotechnology | 2024 | https://conductscience.org/library/papers/39676171 | PubMed |
| 6 | 32315388 | FLT3 inhibition upregulates HDAC8 via FOXO to inactivate p53 and promote maintenance of FLT3-ITD+ acute myeloid leukemia. | Blood | 2020 | https://conductscience.org/library/papers/32315388 | PubMed |
| 7 | 36102738 | HDAC5 Loss Enhances Phospholipid-Derived Arachidonic Acid Generation and Confers Sensitivity to cPLA2 Inhibition in Pancreatic Cancer. | Cancer Res | 2022 | https://conductscience.org/library/papers/36102738 | PubMed |
| 8 | 35152694 | Discovery of DNA-Targeting HDAC Inhibitors with Potent Antitumor Efficacy In Vivo That Trigger Antitumor Immunity. | J Med Chem | 2022 | https://conductscience.org/library/papers/35152694 | PubMed |
| 9 | 37659201 | HDAC11: A novel target for improved cancer therapy. | Biomed Pharmacother | 2023 | https://conductscience.org/library/papers/37659201 | PubMed |
| 10 | 34903992 | Histone Deacetylase Inhibitors, Intrinsic and Extrinsic Apoptotic Pathways, and Epigenetic Alterations of Histone Deacetylases (HDACs) in Hepatocellular Carcinoma. | Iran J Pharm Res | 2021 | https://conductscience.org/library/papers/34903992 | PubMed |
| 11 | 33189849 | Anticancer properties of chimeric HDAC and kinase inhibitors. | Semin Cancer Biol | 2022 | https://conductscience.org/library/papers/33189849 | PubMed |
| 12 | 32903337 | Promoter Hypomethylation and miR-145-5p Downregulation- Mediated HDAC11 Overexpression Promotes Sorafenib Resistance and Metastasis of Hepatocellular Carcinoma Cells. | Front Cell Dev Biol | 2020 | https://conductscience.org/library/papers/32903337 | PubMed |
| 13 | 40164393 | Synthesis and biological evaluation of novel 4-Arylaminoquinolines derivatives as EGFR/HDAC inhibitors. | Bioorg Med Chem Lett | 2025 | https://conductscience.org/library/papers/40164393 | PubMed |
| 14 | 33756235 | Discovery of novel tetrahydrobenzo[b]thiophene-3-carbonitriles as histone deacetylase inhibitors. | Bioorg Chem | 2021 | https://conductscience.org/library/papers/33756235 | PubMed |
| 15 | 36771118 | Entinostat-Bortezomib Hybrids against Multiple Myeloma. | Molecules | 2023 | https://conductscience.org/library/papers/36771118 | PubMed |
| 16 | 25129440 | Down-regulation of HDAC5 inhibits growth of human hepatocellular carcinoma by induction of apoptosis and cell cycle arrest. | Tumour Biol | 2014 | https://conductscience.org/library/papers/25129440 | PubMed |
| 17 | 36831683 | DNA Methylation and Histone Modification in Low-Grade Gliomas: Current Understanding and Potential Clinical Targets. | Cancers (Basel) | 2023 | https://conductscience.org/library/papers/36831683 | PubMed |
| 18 | 35277183 | HDAC7 promotes NSCLC proliferation and metastasis via stabilization by deubiquitinase USP10 and activation of β-catenin-FGF18 pathway. | J Exp Clin Cancer Res | 2022 | https://conductscience.org/library/papers/35277183 | PubMed |
| 19 | 36849955 | Synergistic effect of HDAC inhibitor Chidamide with Cladribine on cell cycle arrest and apoptosis by targeting HDAC2/c-Myc/RCC1 axis in acute myeloid leukemia. | Exp Hematol Oncol | 2023 | https://conductscience.org/library/papers/36849955 | PubMed |
| 20 | 32350373 | Upregulation of CD38 expression on multiple myeloma cells by novel HDAC6 inhibitors is a class effect and augments the efficacy of daratumumab. | Leukemia | 2021 | https://conductscience.org/library/papers/32350373 | PubMed |
Cited by5
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 4 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42883867 | Targeting Aromatase and HDACs in Hormone Receptor-Positive Breast Cancer: Molecular Interplay, Endocrine Resistance and Therapeutic Opportunities. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42883867 | PubMed |
| 42742903 | Transcriptomic and network analyses identify epigenetic regulators of drug-tolerant persister (DTP) subsets in EGFR-mutant HCC827 non-small cell lung cancer. | Genes Genomics | 2026 | https://conductscience.org/library/papers/42742903 | PubMed |
| 42649936 | Overcoming Therapy Resistance in Ovarian Cancer: From Molecular Mechanisms to Emerging Therapeutic Strategies. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42649936 | PubMed |
| 42539113 | Dual Epigenetic and Chaperone Inhibition Disrupts Hypoxia Signaling and Tumor Progression in 3-D Models of Triple-Negative Breast Cancer. | Res Sq | 2026 | https://conductscience.org/library/papers/42539113 | PubMed |
| 42198363 | Hypophosphatemia as a Potential Class Effect of Histone Deacetylase Inhibitors: Evidence from Disproportionality Analysis and Mendelian Randomization Analysis of Drug Targets. | Pharmaceuticals (Basel) | 2026 | https://conductscience.org/library/papers/42198363 | PubMed |
Genes44
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41783166
GET https://conductscience.org/api/papers/v1/41783166/references?page=2